Definium Therapeutics, Inc.
NASDAQ:DFTXBiotechnology
-$0.41 today
- Market cap
- $4.02B
- Beta
- 2.38
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.18
Volume 1.92M
Average 2.67M
Returns on capital
Definium Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-55.3%
avg -57.9%
ROIC
-44.5%
avg -47.7%
ROA
-41.8%
avg -45.4%
Analysis
ROA is currently the strongest return metric at -41.8% versus its period average of -45.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Robert Barrow | Chief Executive Officer & Director | USD 1.05M | 37 | 2.21M | 2.03% |
Daniel Rollings Karlin | Chief Medical Officer | USD 738.73K | 46 | — | — |
Mark R. Sullivan | Chief Legal Officer & Corporate Secretary | USD 638.61K | 55 | — | — |
Brandi L. Roberts | Chief Financial Officer | USD 619.24K | 52 | — | — |
Scott Freeman | Co-Founder & Clinical Advisor | USD 306.2K | 69 | — | — |
Leonard Latchman | Co-founder | — | — | — | — |
Beth Calitri | Vice President of Corporate Communications | — | — | — | — |
Gitanjali Jain | VP & Head of Investor Relations | — | — | — | — |
Stephanie Fagan | Chief Corporate Affairs Officer | — | — | — | — |
Peter Mack | Senior Vice President of Pharmaceutical Development & Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 25, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
17
$7.00M
Net Transaction Value
−$7.00M
Net selling
Most Active
Barrow Robert
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 25, 26Sep 25, 2026 | Wiley Matthew T. Direct | Sell | $113.3K$113,257.29 |
| Sep 25, 26Sep 25, 2026 | Karlin Daniel Direct | Sell | $396.9K$396,894.21 |
| Sep 25, 26Sep 25, 2026 | Sullivan Mark Direct | Sell | $513.8K$513,845.07 |
| Sep 25, 26Sep 25, 2026 | Roberts Brandi Direct | Sell | $123.5K$123,496.89 |
| Sep 25, 26Sep 25, 2026 | Barrow Robert Direct | Sell | $1.2M$1,153,783.50 |
| Sep 3, 26Sep 3, 2026 | Barrow Robert Direct | Sell | $721.7K$721,732.62 |
| Jun 25, 26Jun 25, 2026 | Sullivan Mark Direct | Sell | $585.8K$585,750.24 |
| Jun 25, 26Jun 25, 2026 | Roberts Brandi Direct | Sell | $135.7K$135,675.39 |
| Jun 25, 26Jun 25, 2026 | Barrow Robert Direct | Sell | $1.3M$1,315,236.24 |
| Jun 25, 26Jun 25, 2026 | Karlin Daniel Direct | Sell | $451.9K$451,876.05 |
1–10 of 17
Summary
Insiders reported 0 buys worth $0.00 and 17 sells worth $7.00M over the last 12 months. That adds up to net selling of $7.00M. Barrow Robert was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Definium Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about DFTX's management, answered from reported figures.
Who manages DFTX?
Definium Therapeutics, Inc. (DFTX) lists 10 active executives. The top listed executive is Leonard Latchman, Co-founder.
Are DFTX insiders buying or selling?
Recent insider activity shows net buying of $10.08M.
Continue the stock analysis
Jump to another research area for this company.